NCT04371367View on ClinicalTrials.gov

Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

March 30, 2021

Study Completion Date

March 30, 2021

Conditions
COVID
Interventions
BIOLOGICAL

avdoralimab

intravenous administration of avdoralimab

OTHER

Placebo

intravenous administration of placebo

Trial Locations (1)

13354

Assistance Publique Hôpitaux de Marseille, Marseille

Sponsors

Collaborators (1)

Innate Pharma
All Listed Sponsors
collaborator

Innate Pharma

INDUSTRY

lead

Assistance Publique Hopitaux De Marseille

OTHER